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Previewsbeen proposed in regulating T cell re-
sponses (Pearce et al., 2013), whereas
their impacts on the fate and function of
Teff cells remain to be elucidated. The
further understanding of the interconnec-
tion between environmental nutrient avail-
ability and metabolic reprogramming of
T cells will likely provide new insights
and strategies to improve immune re-
sponses or vaccine efficacy under meta-
bolically restrictive environments.
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Notch receptors are widely expressed and have recognized functions in thymocytes and mature T cells.
In this issue, Laky et al. (2015) show that Notch interactions with Delta-like ligand 4 (DLL4) amplify priming
of naive T cells.There are four mammalian Notch genes,
with Notch1, Notch2, and Notch3 known
to have important roles in thymopoiesis
and the differentiation of CD4+ helper
T cells in the periphery (Radtke et al.,
2013). Notch receptors are capable of
interacting with five ligands, including
Jagged1, Jagged2, Delta-like ligand 1
(DLL1), DLL3, and DLL4 (Radtke et al.,
2013). Ligation of Notch by its ligands re-
sults in proteolytic cleavage of the intra-
cellular domain by gamma secretase.
The resulting subunit, according to what
is called ‘‘canonical signaling,’’ is traf-
ficked to the nucleus, where it coactivates
a number of genes via transcription fac-
tors including RBP-Jk. In noncanonical
signaling, the Notch intracellular domain
drives the transcription of genes indepen-
dently of RBP-Jk. One such route that
has shown relevance in Notch-associatedT cell leukemias entails direct interaction
of the Notch intracellular domain with the
NF-kB signaling pathway (Vilimas et al.,
2007). Effector functions of CD4+ T cells
are augmented by Notch signaling, and
the pattern of Notch ligands on antigen-
presenting cells (APCs) has been shown
to drive differentiation of the various T
helper (Th) lineages (Radtke et al., 2013).
Although its importance inTcell differen-
tiation is well established, the role of Notch
signaling in the priming of naive cells is not
as well studied. Experiments with gamma-
secretase inhibitors (GSIs) have shown
that Notch signaling enhances signals of
the T cell receptor, resulting in increased
expression of activation markers and
proliferation (Adler et al., 2003; Palaga
et al., 2003). Furthermore, overexpression
of the intracellular domain of Notch1 en-
hances T cell proliferation (Adler et al.,2003). In this issue of Immunity, Laky
et al. (2015) add to our knowledge of
Notch signaling during the activation of
naive T cells with reductionist experiments
demonstrating a costimulatory role for
Notch-DLL4 interactions in T cell priming.
To precisely control activation condi-
tions, Laky et al. transfected CD80+ and
CD80 fibroblast lines expressing major
histocompatibility complex (MHC) class
II glycoproteins and the integrin ICAM-1
with physiological amounts of DLL4.
Naive CD4+ T cells showed increased
sensitivity to antigen in the presence of
DLL4, with enhanced CD69 upregulation
and proliferation over a wide range of an-
tigen concentrations. Interestingly, DLL4,
which was found to be expressed on
a subset of CD11c+ splenic dendritic
cells, enhanced T cell activation only if

























Figure 1. Signals to Notch Receptors on Naive T Cells Come from Other T Cells or from
Antigen-Presenting Cells
In this issue, Laky et al. (2015) show that DLL4 acting through Notch receptors drives the transcription
factor RBP-Jk, which in turn amplifies the PI3K-Akt-mTOR pathway (thick red lines) in a CD28-dependent
manner. However, the exact molecules downstream of RBP-Jk that potentiate PI3K are unclear. The
resulting advantage for growth and metabolism impels T cell activation and effector functions.
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PreviewsCD28. Additionally, experiments with
mice harboring dendritic cells with condi-
tionally ablated RBP-Jk demonstrated an
absolute requirement for RBP-Jk in DLL4-
mediated upregulation of metabolic
genes. Together, these two results sug-
gest an indirect pathway wherein upregu-
lation of RBP-Jk-dependent genes results
in the potentiation of CD28-mediated
costimulation (Figure 1). The genes down-
stream of Notch and RBP-Jk that
enhance glycolysis through the CD28-
mediated PI3K signaling pathway are not
identified, and future studies will be
necessary to further elucidate the path-
way connecting Notch signaling with the
PI3K-Akt-mTOR pathway.
The necessity of CD28 signaling shown
here differs from previous work (Adler
et al., 2003), which revealed that blocking
Notch cleavage reduces T cell proliferation
when stimulated by beads coated either
with both CD3 and CD28 antibodies or
CD3 antibody alone. In the work of Adler
et al. and other studies, the spontaneous
cleavage of Notch upon T cell receptor
(TCR) triggering (but in the absenceof Notch ligands) is observed but is not
well understood. Furthermore, activated
T cells may themselves express Notch
ligands, including DLL1 (Dongre et al.,
2014). These findings complicate interpre-
tation of the reductionist studies presented
by Laky et al. in their dissection of DLL4-
mediated signals into T cells. In addition
to enhancing T cell activation, Notch
signaling upon ligation by DLL4 also in-
creases thesurvivalofblastingcellsbypro-
moting theexpressionof antiapoptotic fac-
tors such asBcl-2, c-FLIP, and inhibitors of
apoptosis (IAPs) (Helbig et al., 2012). Thus,
Notch signaling amplifies T cell responses
through multiple mechanisms.
Laky et al. show that a major con-
sequence of DLL4-mediated Notch sig-
naling in naive T cells is to increase cell-
surface expression of transferrin receptor
and amino acid and glucose (Glut1) trans-
port proteins. The upregulation of these
metabolic genes was due to increased
activity in the PI3K-Akt-mTOR pathway
as measured by phosphorylation of S6,
4EBP1, and GSK3b. These results fit
with the well-accepted transition of naiveImmunityT cells from oxidative phosphorylation
to glycolysis during the activation and
effector phases. Furthermore, quiescent
memory CD4+ T cells, unlike memory
CD8+ T cells, require basal glycolysis
for survival. Maekawa et al. (2014) have
recently shown that insulin-mediated
upregulation of the glucose transporter
Glut1 in memory CD4+ T cells is depen-
dent on RBP-Jk. This result supports the
notion that tonic signaling through Notch
is necessary for maintaining a glycolytic
metabolic state for memory CD4+ T cells.
The principal Notch ligand for supporting
memory cells has not been identified,
though deletion of DLL1 on CD11c+ den-
dritic cells results in diminished survival
of memory T cells in the bone marrow
(Maekawa et al., 2014). These results sub-
stantiate the role of Notch signaling into
T cells in promoting glycolytic
metabolism.
The results of Laky et al. are compatible
with studies showing a role for Notch in
enhancing T cell activation and prolifera-
tion (Adler et al., 2003; Palaga et al.,
2003), though there is significant disagree-
ment with an earlier reductionist study
(Eagar et al., 2004). Using crosslinking an-
tibodies, Eagar et al. showed that signaling
through Notch1 dramatically inhibits T cell
activation in response to immobilized CD3
and CD28 antibodies plus either anti-
bodies that crosslinkNotchormyc-tagged
fusion proteins of Jagged1 or DLL1. It is
difficult to reconcile the results of Laky
et al. and Helbig et al. with the work of
Eagar et al. If organization of Notch ligands
is naturally monomeric, it is possible that
multivalent ligation of Notch results in
diminished activity, either directly (e.g.,
by unnatural dimerization) or indirectly
(e.g., by making less free Notch available
for dimerization). The dose of Notch sig-
nals seems to be important, too, in that
cell-surface ligation with artificial ligands
or transduction of T cells with overex-
pressed Notch intracellular domains may
result in aberrant responses. Laky et al.
showed an absolute dependence on
RBP-Jk for the Notch-mediated effects
on T cell activation and expression of
metabolic genes. However, this result is
incongruous with recent work showing
that in T cells bearing conditionally ablated
RBP-Jk and stimulated with CD3 plus
CD28 antibodies, the intracellular domain
of Notch1 enhances T cell activation (Don-
gre et al., 2014); in other words, canonical42, January 20, 2015 ª2015 Elsevier Inc. 7
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PreviewsNotch signaling is dispensable for activa-
tion of CD4+ T cells. These data indicate
that there may be a role for both RBP-Jk-
dependent and noncanonical signals in
T cell activation. The specifics of themilieu
in which T cells receive activating signals
and the phenotype of the APCs are likely
to play a dominant role in determining the
mode of Notch signaling, as well as the
downstream effects. Further experiments
will be necessary to resolve these
discrepancies.
Costimulation is known to play a key role
in promoting glucose metabolism during
T cell activation (Frauwirth et al., 2002),
and Laky et al. show that Notch-mediated
enhancement of costimulation is required
for a potent antitumor response. Further-
more, inhibition of Notch controls autoim-
munity in an experimental autoimmune
encephalomyelitis (EAE) model by
decreasing glucose uptake (Maekawa8 Immunity 42, January 20, 2015 ª2015 Elsevet al., 2014). Thus, modulation of Notch-
mediated metabolic switches in T cells
could be an important therapeutic tool. In
summary, Laky et al. identify a link be-
tween Notch, CD28 signaling, and meta-
bolism in peripheral T cells. In so doing,
they demonstrate that sensitivity to anti-
gen must be taken down a notch for
optimal T cell responses.REFERENCES
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The number of T cells specific for various antigens can vary dramatically. In this issue of Immunity, Nelson
et al. (2015) report that these differences might be, at least in part, set by the number of cross-reactive self
peptides encountered by T cells during development.How many T cells recognize a given
peptide antigen presented by a major his-
tocompatibility complex (MHC)? Gener-
ally speaking, the more naive T cells that
recognize a peptide antigen bound to
MHC, the stronger the resulting immune
response (Jenkins and Moon, 2012). But
this conceptually simple question has
proven difficult to answer in practice.
Several years ago, Jenkins and col-
leagues devised an elegant method to
determine the number of T cells that recog-
nize anantigen: by enriching T cells stained
with peptide-MHC (pMHC) tetramers of
interest, they can directly count naive, an-
tigen-specific T cells (Moon et al., 2007).Using this technique, they have found
that the number of naive T cells that recog-
nize a given pMHC is consistent from
mouse to mouse, but can vary by orders
of magnitude between different pMHCs
(Moon et al., 2007). But what causes these
differences? In this issue of Immunity,
Nelson et al. showed that T cells recognize
many (but not all) MHCs displaying pep-
tides that share T cell receptor (TCR) con-
tact epitopes. They also found the number
of T cells that recognize a given pMHC in
the mature T cell repertoire is negatively
correlated with the number of self antigens
that share that pMHC’s TCR contact
epitope, likely due to editing in the thymusduring T cell development (Nelson et al.,
2015) (Figure 1).
Nelson et al. took advantage of two
properties of pMHC-TCR interactions to
find potentially cross-reactive peptides
with an array of model antigens bound to
the mouse class II MHC I-Ab. First, by
knowing the binding register of peptides
for class II MHC, they predicted which
peptide side chains would be seen by
the TCR (position or ‘‘P’’2, 3, 5, and 8)
and which would primarily bind the MHC
(P1, 4, 6, and 9) (Jones et al., 2006). Sec-
ond, because TCR cross reactivity can
occur through limited changes to TCR
contact residues and a larger degree of
